Filing Details
- Accession Number:
- 0001127602-10-007291
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-03-03 12:00:00
- Reporting Period:
- 2010-03-01
- Filing Date:
- 2010-03-03
- Accepted Time:
- 2010-03-03 19:05:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 729922 | Osi Pharmaceuticals Inc | OSIP | In Vitro & In Vivo Diagnostic Substances (2835) | 133159796 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1314821 | Lundemose Anker Md, Ph.d, Dsc | C/O Osi Pharmaceuticals, Inc. 41 Pinelawn Road New York NY 11747 | Evp, Corp. Dev & Strategic Pln | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2010-03-01 | 15,200 | $35.10 | 46,823 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2010-03-01 | 13,000 | $29.77 | 59,823 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2010-03-01 | 29,200 | $55.20 | 30,623 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2010-03-01 | 15,200 | $0.00 | 15,200 | $35.10 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2010-03-01 | 13,000 | $0.00 | 13,000 | $29.77 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2005-02-11 | 2014-02-10 | No | 4 | M | Direct |
| 5,000 | 2007-06-13 | 2013-06-12 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a Rule 10b5-1 trading plan adopted on November 3, 2009.
- The price reported represents the weightedaverage sales price of shares sold in multiple transactions at prices ranging from $55.15 to $55.32 per share. The Reporting Person will provide, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- One third of the stock options became exercisable one year after the date of the grant and the remainder vested ratably on a monthly basis over the succeeding 24 months.
- 25% of the option became exercisable one year after the date of grant and the remainder vests ratably on an annual basis over the succeeding 3 years.
- Includes only options with the same termination date.
Billionaire Hedge Funds
